Rezubio Pharmaceuticals advanced RZ-520 into Phase I after IND clearance by both the FDA and China’s NMPA, with dosing beginning in healthy volunteers for chronic respiratory diseases. The dual-agency clearance signals cross-border readiness for early clinical development. Separately, Acepodia obtained FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate aimed at unresectable or metastatic hepatocellular carcinoma. The company plans to initiate a Phase I study, targeting a patient population with limited durable options and high unmet need. Together, the updates show continued pipeline momentum for early-stage biologics and targeted ADCs across respiratory and liver oncology indications—two areas where dose-finding and safety signals will be closely watched.